 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Librela |
| AHFS/Drugs.com | Veterinary Use |
| License data |
|
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
Bedinvetmab, sold under the brand name Librela is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs.[3][4][5] Librela is sponsored by Zoetis.[5][6]
The most common side effects include increased blood urea nitrogen (an indicator of kidney function), urinary tract infection, bacterial skin infection, skin irritation (dermatitis), rash (erythema) or pain at injection site, vomiting (emesis), and weight loss (anorexia).[5]
Bedinvetmab was approved for medical use in the European Union in November 2020,[4] and in the United States in May 2023.[5][6] Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.[5]
- ^ "Librela Product information". Health Canada.
- ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
- ^ a b "Librela (bedinvetmab injection) Injectable Solution Dogs". Zoetis Inc. U.S. Food and Drug Administration. NADA 141-562.
- ^ a b c "Librela EPAR". European Medicines Agency (EMA). 21 February 2022. Archived from the original on 16 March 2023. Retrieved 13 May 2023.
- ^ a b c d e "FDA Approves First Monoclonal Antibody for Dogs with Osteoarthritis Pain". U.S. Food and Drug Administration (FDA). 5 May 2023. Retrieved 13 May 2023.
This article incorporates text from this source, which is in the public domain.
- ^ a b "Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 – via Business Wire.
